BioSpace News Archive

IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions business unit.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus trimer mRNA vaccine.

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the previously granted U.S. patent No. 11,235,169 (the ’169 patent) for the BF-RhodoLED® XL illumination device is now listed in the U.S. Food and Drug Administration (FDA) publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the Orange Book.

Extremity Medical, a global medical device company focused on the development of innovative implants and instruments for upper and lower extremities, announced Steven L. Haddad, MD has joined Extremity Medical as Chief Clinical Officer.

Dialectic Therapeutics, Inc. (Dialectic®), a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DT2216 for the treatment of T-cell lymphoma.

Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), today announced that the first patient has been enrolled in the quadruple-blinded sham-controlled AIM HIGHer IDE clinical study (Assessment of Implantable CCM in the Heart Failure Group with Higher Ejection Fraction, NCT: 05064709) evaluating CCM® therapy for patients who have left ventricular ejection fraction ranging between 40% and 60% inclusive.

Melinta Therapeutics announces the appointment of Dr. Peter Piliero as Vice President of Medical Affairs, effective today.

Amsterdam, the Netherlands and Orlando, Florida, USA – Royal Philips, a global leader in health technology, announced its latest introductions in analytics and interoperability solutions at the HIMSS22 Global Health Conference & Exhibition.

The global smart healthcare market size is expected to hit US$ 482.25 billion by 2027 from valued at US$ 145.32 billion in 2020, poised to grow at a CAGR of 19.7% between 2020 and 2027.

According to Precedence Research, the transplantation market size is expected to reach over US$ 27.07 billion by 2027 and is expanding growth at a CAGR of 9.5% during the forecast period 2020 to 2027.